MYC and cancer: Yet these examples, involving alterations in chromosomal architecture, underestimate the true frequency with which MYC is dysregulated in cancer as aberrant signaling by many mutant growth factor pathways converge on MYC and promote its over-expression in the absence of structural changes [130,131,132].